MetaCap

Vicore Pharma Holding AB ADR (VCRE)

NASDAQ: VCREHealth CareBiotechnology: Pharmaceutical PreparationsUSD

9.41-0.5049 (-5.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VCRE stock chart

Technical analysis

Key statistics

All statistics
Market cap
$264.89M
EPS (TTM)
-$2.04
52-week range
7.88 – 17.80
Day range
9.41 – 10.05
Volume / Avg
12.97K / 23.31K
Beta
—

52-week range

$7.88$17.80

VCRE stock today

On Nov 20, VCRE ended the session at $9.41, shedding $0.5049 (5.09%), versus the S&P 500's 3.70% decline. At this level, VCRE sits near the bottom of its 52-week range of $7.88 to $17.80: 47.2% below the high, set on Jul 7, 2026 and 19.4% above the low. Vicore Pharma AB has posted a net loss over the last twelve months (EPS of -$2.04), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Vicore Pharma AB

Company profile

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Ahmed S. Mousa J.D.
Headquarters
Stockholm
Employees
50

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$24.35+158.90%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $14.54High $34.01

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Vicore Pharma AB peers

Health Care sector
VCRE peer companies
CompanyPrice% ChgMarket capCompare
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs VCRE
ALTAltimmune Inc.1.33-5.67%$258.80Mvs VCRE
PRLDPrelude Therapeutics Incorporated3.23-0.77%$258.63Mvs VCRE
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs VCRE
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs VCRE
QTTBQ32 Bio Inc.8.34-1.65%$249.57Mvs VCRE
FULCFulcrum Therapeutics Inc.3.69-0.54%$281.85Mvs VCRE
TTRXTurn Therapeutics Inc.8.10-6.31%$247.49Mvs VCRE

Indexes, lists and sector

Vicore Pharma AB stock FAQ

What is Vicore Pharma AB's stock price today?

VCRE last traded at $9.41 as of Nov 20, 4:00 PM EST, down 5.09% on the day. Prices are delayed at least 15 minutes.

Who is Vicore Pharma AB's CEO?

Mr. Ahmed S. Mousa J.D. is the chief executive officer of Vicore Pharma Holding AB ADR, which has about 50 employees.

What is the VCRE 52-week high?

The 52-week high for VCRE is $17.80 and the 52-week low is $7.88. The stock is currently 47.2% below its high.

Compare VCRE